D. Michael Lovelock, PhD

Share
Print
Share
Print

I am a board-certified associate attending medical physicist focused on the development, safe clinical implementation, and outcomes of high-dose radiotherapy given in very few treatments. These treatments require a high degree of accuracy in positioning the tumor at the time the radiation is delivered. I have helped to develop specialized clinical procedures to perform these treatments, such as the careful immobilization of patients with spinal tumors, use of compression and anesthesia for the treatment of abdominal tumors, and quality assurance of the advanced imaging equipment used to position or track tumors.

I am collaborating with radiation oncologists Joshua Yamada and Mark Bilsky to study treatment failure patterns and dosimetric factors that lead to the successful management of spinal tumors. I am also working with Michael Zelefsky to improve the accuracy of dose delivery using a radiofrequency tumor tracking system.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

D. Michael Lovelock discloses the following relationships and financial interests:

  • Advanced Micro Devices, Inc
    Ownership / Equity Interests
  • Amazon.com, Inc.
    Ownership / Equity Interests
  • Cisco Systems, Inc.
    Ownership / Equity Interests
  • NVIDIA Corporation
    Ownership / Equity Interests
  • Oracle Corporation
    Ownership / Equity Interests
  • The Home Depot
    Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures